These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 26714188

  • 1. Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.
    Pialoux G, Marcelin AG, Despiégel N, Espinas C, Cawston H, Finkielsztejn L, Laurisse A, Aubin C.
    PLoS One; 2015; 10(12):e0145885. PubMed ID: 26714188
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.
    Pialoux G, Marcelin AG, Cawston H, Guilmet C, Finkielsztejn L, Laurisse A, Aubin C.
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):83-91. PubMed ID: 28741965
    [Abstract] [Full Text] [Related]

  • 3. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
    Tremblay G, Chounta V, Piercy J, Holbrook T, Garib SA, Bukin EK, Punekar YS.
    Value Health Reg Issues; 2018 Sep; 16():74-80. PubMed ID: 30296624
    [Abstract] [Full Text] [Related]

  • 4. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP.
    Clin Infect Dis; 2016 Mar 15; 62(6):784-91. PubMed ID: 26658053
    [Abstract] [Full Text] [Related]

  • 5. Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada.
    Despiégel N, Anger D, Martin M, Monga N, Cui Q, Rocchi A, Pulgar S, Gilchrist K, Refoios Camejo R.
    Infect Dis Ther; 2015 Sep 15; 4(3):337-53. PubMed ID: 26099626
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.
    J Med Econ; 2015 Sep 15; 18(10):763-76. PubMed ID: 25934146
    [Abstract] [Full Text] [Related]

  • 7. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
    Akil B, Blick G, Hagins DP, Ramgopal MN, Richmond GJ, Samuel RM, Givens N, Vavro C, Song IH, Wynne B, Ait-Khaled M, VIKING-4 study team.
    Antivir Ther; 2015 Sep 15; 20(3):343-8. PubMed ID: 25321146
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients.
    Restelli U, Rizzardini G, Antinori A, Lazzarin A, Bonfanti M, Bonfanti P, Croce D.
    Ther Clin Risk Manag; 2017 Sep 15; 13():787-797. PubMed ID: 28721059
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States.
    Butler K, Anderson SJ, Hayward O, Jacob I, Punekar YS, Evitt LA, Oglesby A.
    J Manag Care Spec Pharm; 2021 Jul 15; 27(7):891-903. PubMed ID: 34185564
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K, Halfpenny NJA, Snedecor SJ, Punekar YS.
    BMC Infect Dis; 2021 Feb 26; 21(1):222. PubMed ID: 33637050
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.
    Elbasha EE, Szucs T, Chaudhary MA, Kumar RN, Roediger A, Cook JR, Opravil M.
    HIV Clin Trials; 2009 Feb 26; 10(4):233-53. PubMed ID: 19723611
    [Abstract] [Full Text] [Related]

  • 15. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
    Moreno Guillen S, Losa García JE, Berenguer Berenguer J, Martínez Sesmero JM, Cenoz Gomis S, Graefenhain R, Lopez Sanchez-Cambronero D, Parrondo Garcia FJ.
    Farm Hosp; 2017 Sep 01; 41(5):601-610. PubMed ID: 28847249
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain.
    Chaudhary MA, Moreno S, Kumar RN, Nocea G, Elbasha E.
    AIDS Res Hum Retroviruses; 2009 Jul 01; 25(7):679-89. PubMed ID: 19552590
    [Abstract] [Full Text] [Related]

  • 17. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
    Curtis L, Nichols G, Stainsby C, Lim J, Aylott A, Wynne B, Clark A, Bloch M, Maechler G, Martin-Carpenter L, Raffi F, Min S.
    HIV Clin Trials; 2014 Jul 01; 15(5):199-208. PubMed ID: 25350958
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
    Todd S, Rafferty P, Walker E, Hunter M, Dinsmore WW, Donnelly CM, McCarty EJ, Quah SP, Emerson CR.
    Int J STD AIDS; 2017 Oct 01; 28(11):1074-1081. PubMed ID: 28118801
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.